<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326128</url>
  </required_header>
  <id_info>
    <org_study_id>1703346</org_study_id>
    <nct_id>NCT03326128</nct_id>
  </id_info>
  <brief_title>High Dose Bupropion for Smoking Cessation</brief_title>
  <official_title>High Dose Bupropion Treatment for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the benefit of administering Bupropion XL (BUP-XL) to heavy
      smokers who also experience psychiatric symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomly assigned to either receive 300 mg of BUP-XL or 450 mg of BUP-XL
      with an aim to quit smoking. They will take the medication for 8 weeks while simultaneously
      receiving counseling to set a quit date and stay motivated to quit. Medication will be
      administered for 4 weeks before and 4 weeks after designated quit-date. Post-treatment
      follow-up appointment will be scheduled for 8, 16, and 26 weeks post treatment so assess
      commitment to quitting and overall success of the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to receive either 300 or 450 mg of Bupropion XL.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Participant will be unaware of which medication condition they have been assigned to, the care provider will not know which dose of medication they are distributing.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Point prevalence Abstinence (PPA) [change in abstinence reports will be assessed]</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>self report of smoking status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>smoking cessation milestones</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>from smoking timeline follow back interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>29 Item Inventory of Depressive and Anxious Symptomology - general depression subscale</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>general depression: mean score of items, range = 1-5, higher scores = more depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>29 Item Inventory of Depressive and Anxious Symptomology - social anxiety subscale</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>social anxiety: mean score of items, range = 1-5, higher scores = more social anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>29 Item Inventory of Depressive and Anxious Symptomology - traumatic intrusions subscale</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>traumatic intrusions subscale: mean score of items, range = 1-5, higher scores = more traumatic intrusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18- item adult self report scale for Attention deficit/Hyperactivity disorder (ADHD)</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>ADHD symptom report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snaithe-Hamilton Pleasure Scale (SHAPS)</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>Anhedonia scale - range: 1- 4, higher scores =higher reports of pleasure, scored using a mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective body weight</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>via medical grade scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body adiposity via bioimpedence monitor</measure>
    <time_frame>baseline session, 4, 8, 16, 26 weeks post quite date</time_frame>
    <description>measures body fat percentage/ BMI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Smoking, Tobacco</condition>
  <condition>Smoking (Tobacco) Addiction</condition>
  <condition>Cessation, Tobacco</condition>
  <condition>Anhedonia</condition>
  <arm_group>
    <arm_group_label>BUP-300</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 300 mg/day and will also receive standard smoking cessation counseling for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BUP-450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 450 mg/day and will also receive standard smoking cessation counseling for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion hydrochloride extended release</intervention_name>
    <description>Antidepressant that is also effective in smoking cessation</description>
    <arm_group_label>BUP-300</arm_group_label>
    <arm_group_label>BUP-450</arm_group_label>
    <other_name>Bupropion XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  smokes &gt;= 10 cigarettes per day for &gt;= 2 years

          -  has breath CO ppm &gt;= 10 ppm on intake

          -  Age 21 - 65

        Exclusion Criteria:

          -  Past year moderate- severe DSM-5 non-tobacco substance use disorder (4+ symptoms)

          -  Possible drug contraindications (Panic, bipolar, bulimia, anorexia, insomnia, suicidal
             ideation, alcohol withdrawal, seizures, severe hypertension, renal/hepatic impairment,
             angle closure glaucoma)

          -  current use of other cessation medication

          -  current use of e-cigarettes or other tobacco products &gt; 2X/week

          -  history of bupropion use

          -  current anti-psychotic, anxiolytic, antidepressant, or psychostimulant medication use

          -  currently or plan to be pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam M Leventhal, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam M Leventhal, PhD</last_name>
    <phone>323-442-8222</phone>
    <email>adam.leventhal@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julianne T De La Cerda, BA</last_name>
    <phone>323-442-2598</phone>
    <email>jdelacer@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC Health Sciences Campus</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julianne T De La Cerda, BA</last_name>
      <phone>323-442-2598</phone>
      <email>jdelacer@usc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Leventhal AM, Kahler CW, Ray LA, Zimmerman M. Refining the depression-nicotine dependence link: patterns of depressive symptoms in psychiatric outpatients with current, past, and no history of nicotine dependence. Addict Behav. 2009 Mar;34(3):297-303. doi: 10.1016/j.addbeh.2008.11.008. Epub 2008 Nov 21.</citation>
    <PMID>19062199</PMID>
  </reference>
  <reference>
    <citation>Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, Abrams D, Miller IW. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res. 2007 Jul;9(7):721-30.</citation>
    <PMID>17577801</PMID>
  </reference>
  <reference>
    <citation>Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-13.</citation>
    <PMID>16027765</PMID>
  </reference>
  <reference>
    <citation>Ameringer KJ, Chou CP, Leventhal AM. Shared versus specific features of psychological symptoms and cigarettes per day: structural relations and mediation by negative- and positive-reinforcement smoking. J Behav Med. 2015 Apr;38(2):224-36. doi: 10.1007/s10865-014-9597-y. Epub 2014 Sep 18.</citation>
    <PMID>25231408</PMID>
  </reference>
  <reference>
    <citation>Leventhal AM, Mickens L, Dunton GF, Sussman S, Riggs NR, Pentz MA. Tobacco use moderates the association between major depression and obesity. Health Psychol. 2010 Sep;29(5):521-8. doi: 10.1037/a0020854.</citation>
    <PMID>20836607</PMID>
  </reference>
  <reference>
    <citation>Boutelle KN, Monreal T, Strong DR, Amir N. An open trial evaluating an attention bias modification program for overweight adults who binge eat. J Behav Ther Exp Psychiatry. 2016 Sep;52:138-146. doi: 10.1016/j.jbtep.2016.04.005. Epub 2016 Apr 16.</citation>
    <PMID>27116704</PMID>
  </reference>
  <reference>
    <citation>Boutelle KN, Braden A, Douglas JM, Rhee KE, Strong D, Rock CL, Wilfley DE, Epstein L, Crow S. Design of the FRESH study: A randomized controlled trial of a parent-only and parent-child family-based treatment for childhood obesity. Contemp Clin Trials. 2015 Nov;45(Pt B):364-370. doi: 10.1016/j.cct.2015.09.007. Epub 2015 Sep 8.</citation>
    <PMID>26358536</PMID>
  </reference>
  <reference>
    <citation>Boutelle KN, Liang J, Knatz S, Matheson B, Risbrough V, Strong D, Rhee KE, Craske MG, Zucker N, Bouton ME. Design and implementation of a study evaluating extinction processes to food cues in obese children: the Intervention for Regulations of Cues Trial (iROC). Contemp Clin Trials. 2015 Jan;40:95-104. doi: 10.1016/j.cct.2014.11.011. Epub 2014 Nov 22.</citation>
    <PMID>25461494</PMID>
  </reference>
  <reference>
    <citation>Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA. 2014 Jan 8;311(2):155-63. doi: 10.1001/jama.2013.283185.</citation>
    <PMID>24399554</PMID>
  </reference>
  <reference>
    <citation>Leventhal AM, Munafò M, Tidey JW, Sussman S, Monterosso JR, Sun P, Kahler CW. Anhedonia predicts altered processing of happy faces in abstinent cigarette smokers. Psychopharmacology (Berl). 2012 Jul;222(2):343-51. doi: 10.1007/s00213-012-2649-5. Epub 2012 Feb 4.</citation>
    <PMID>22311383</PMID>
  </reference>
  <reference>
    <citation>Leventhal AM, Trujillo M, Ameringer KJ, Tidey JW, Sussman S, Kahler CW. Anhedonia and the relative reward value of drug and nondrug reinforcers in cigarette smokers. J Abnorm Psychol. 2014 May;123(2):375-86. doi: 10.1037/a0036384.</citation>
    <PMID>24886011</PMID>
  </reference>
  <reference>
    <citation>Leventhal AM, Ameringer KJ, Osborn E, Zvolensky MJ, Langdon KJ. Anxiety and depressive symptoms and affective patterns of tobacco withdrawal. Drug Alcohol Depend. 2013 Dec 1;133(2):324-9. doi: 10.1016/j.drugalcdep.2013.06.015. Epub 2013 Jul 26.</citation>
    <PMID>23896304</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Adam Leventhal</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Bupropion XL</keyword>
  <keyword>Anhedonia</keyword>
  <keyword>Heavy Smokers</keyword>
  <keyword>Smoking cessation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anhedonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

